Document Detail


Orally administered RDP58 reduces the severity of dextran sodium sulphate induced colitis.
MedLine Citation:
PMID:  12379615     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Oral administration of the novel anti-inflammatory peptide RDP58 markedly reduced the severity of dextran sulphate sodium (DSS) colitis as determined by clinical and quantitative histological criteria. The architecture of the colonic epithelium in DSS treated mice receiving RDP58 remained relatively normal compared with that of control DSS treated animals. 5-Bromo-2'-deoxyuridine (BrdU) labelling studies showed a pronounced inhibition of colonic epithelial cell proliferation during DSS treatment, which was partially reversed by RDP58 therapy. Remarkably, RDP58 almost completely prevented colonic epithelial cell death induced by DSS treatment. RDP58 therapy also inhibited the accumulation of neutrophils in the colon of DSS treated mice and effectively down regulated tumour necrosis factor (TNF) expression. Preservation of the intestinal mucosa by RDP58 may thus derive from its influence on TNF expression as well as additional anti-inflammatory properties. These findings indicate that RDP58 represents a new, orally available agent potentially useful in the treatment of inflammatory bowel disease.
Authors:
R Boismenu; Y Chen; K Chou; A El-Sheikh; R Buelow
Related Documents :
11755925 - Propionyl-l-carnitine reduces intimal hyperplasia after injury in normocholesterolemic ...
25237585 - Generalization of the receiver-operating characteristic curve to determine the normal h...
7767395 - A case of unexplained mild rh (d) haemolytic disease in utero.
2088735 - Transplacental transport of lead.
1894455 - Tricyclic drugs in pregnancy and lactation: a preliminary report.
20117775 - Perinatal risk in singleton pregnancies after in vitro fertilization.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Annals of the rheumatic diseases     Volume:  61 Suppl 2     ISSN:  0003-4967     ISO Abbreviation:  Ann. Rheum. Dis.     Publication Date:  2002 Nov 
Date Detail:
Created Date:  2002-10-15     Completed Date:  2002-12-12     Revised Date:  2009-11-18    
Medline Journal Info:
Nlm Unique ID:  0372355     Medline TA:  Ann Rheum Dis     Country:  England    
Other Details:
Languages:  eng     Pagination:  ii19-24     Citation Subset:  IM    
Affiliation:
Department of Immunology, The Scripps Research Institute, La Jolla, California 92037, USA. rboismenu@repligen.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Disease
Administration, Oral
Animals
Anti-Inflammatory Agents / therapeutic use*
Apoptosis / drug effects
Cell Division / drug effects
Colitis / chemically induced,  pathology,  prevention & control*
Dextran Sulfate
Epithelial Cells / drug effects,  pathology
Female
Intestinal Mucosa / drug effects,  pathology
Mice
Mice, Inbred C57BL
Neutrophil Infiltration / drug effects
Peptides / therapeutic use*
Tumor Necrosis Factor-alpha / biosynthesis
Grant Support
ID/Acronym/Agency:
AI40616/AI/NIAID NIH HHS
Chemical
Reg. No./Substance:
0/Anti-Inflammatory Agents; 0/Peptides; 0/Tumor Necrosis Factor-alpha; 151232-75-6/allotrap; 9042-14-2/Dextran Sulfate
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Is NF-kappaB a useful therapeutic target in rheumatoid arthritis?
Next Document:  Role of RANKL and RANK in bone loss and arthritis.